New Diarylamine KV10.1 Inhibitors and Their Anticancer Potential

2022 | journal article. A publication with affiliation to the University of Göttingen.

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​New Diarylamine KV10.1 Inhibitors and Their Anticancer Potential​
Gubič, Š.; Toplak, Ž.; Shi, X.; Dernovšek, J.; Hendrickx, L. A.; Pinheiro-Junior, E. L. & Peigneur, S. et al.​ (2022) 
Pharmaceutics14(9) pp. 1963​.​ DOI: https://doi.org/10.3390/pharmaceutics14091963 

Documents & Media

document.pdf5.85 MBAdobe PDF

License

Published Version

Attribution 4.0 CC BY 4.0

Details

Authors
Gubič, Špela; Toplak, Žan; Shi, Xiaoyi; Dernovšek, Jaka; Hendrickx, Louise Antonia; Pinheiro-Junior, Ernesto Lopes; Peigneur, Steve; Tytgat, Jan; Pardo, Luis A. ; Peterlin Mašič, Lucija; Tomašič, Tihomir
Abstract
Expression of the voltage-gated potassium channel KV10.1 (Eag1) has been detected in over 70% of human cancers, making the channel a promising new target for new anticancer drug discovery. A new structural class of KV10.1 inhibitors was prepared by structural optimisation and exploration of the structure–activity relationship of the previously published hit compound ZVS-08 (1) and its optimised analogue 2. The potency and selectivity of the new inhibitors between KV10.1 and hERG were investigated using whole-cell patch-clamp experiments. We obtained two new optimised KV10.1 inhibitors, 17a and 18b, with improved nanomolar IC50 values of 568 nM and 214 nM, respectively. Compound 17a exhibited better ratio between IC50 values for hEAG1 and hERG than previously published diarylamine inhibitors. Compounds 17a and 18b moderately inhibited the growth of the KV10.1-expressing cell line MCF-7 in two independent assays. In addition, 17a and 18b also inhibited the growth of hERG-expressing Panc-1 cells with higher potency compared with MCF-7 cells. The main obstacle for newly developed diarylamine KV10.1 inhibitors remains the selectivity toward the hERG channel, which needs to be addressed with targeted drug design strategies in the future.
Issue Date
2022
Journal
Pharmaceutics 
Organization
Max-Planck-Institut für Experimentelle Medizin 
eISSN
1999-4923
Language
English

Reference

Citations


Social Media